Krishna Bilas Ghimire

Learn More
We estimate the role of benefits and peer effects in technology adoption using data from randomized distribution of menstrual cups in Nepal. Using individual randomization, we estimate causal effects of peer exposure on adoption; using differences in potential returns we estimate effects of benefits. We find both peers and value influence adoption. Using(More)
We estimate the role of peer effects in technology adoption using data from a randomized distribution of menstrual cups in Nepal. Using individual randomization, we estimate causal effects of peer exposure on adoption. We find strong evidence of peer effects: two months after distribution, one additional friend with access to the menstrual cup increases(More)
There are four kinds of abstracts in this bibliography: those written by the authors of this volume; those written by the authors of the entry concerned, those written by editors of journals or publishers; and abstracts from database services or existing annotated bibliographies. The origin of the abstract is given in full in all but the first instance.(More)
BACKGROUND Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. Long-term survivors from AML may be at higher risk of second primary malignancies. PATIENTS AND METHODS We selected adult patients with AML aged≥18 years from the National Cancer Institute's Surveillance, Epidemiology and End RESULTS (SEER 13) database. We used(More)
A 71-year-old woman came to the hospital because of generalized weakness, fatigue, and exertional dyspnea. She had a history of anemia, recurrent urinary tract infections, and hyperactive bladder. She had been taking nitrofurantoin for a urinary tract infection and phenazopyridine for dysuria, and she noticed that her urine was dark-colored. She was of(More)
422 Background: Since approval of sorafenib in December 2005, several targeted therapeutic agents have been approved by the FDA for the treatment of advanced renal cell carcinoma. This study was conducted to find out whether the improvements in survival of advanced RCC patients with targeted agents have translated into survival benefit in population-based(More)
BACKGROUND Survival in acute myeloid leukemia (AML) has improved in younger patients over the last decade. This study was conducted to evaluate the relative survival rates in older AML patients over two decades in the US. MATERIAL AND METHODS We analyzed Surveillance, Epidemiology, and End Results (SEER) registry database to evaluate relative survival(More)